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The β-chain of human interleukin 12 (IL-12) contains at posi-
tion 319–322, the sequence Trp-x-x-Trp. In human RNase 2
this is the recognition motif for a new, recently discovered
posttranslational modification, i.e., the C-glycosidic attach-
ment of a mannosyl residue to the side chain of tryptophan.
Analysis of C-terminal peptides of recombinant IL-12
(rHuIL-12) by mass spectrometry and NMR spectroscopy re-
vealed that Trp-319β is (partially) C-mannosylated. This
finding was extended by in vitro mannosylation experiments,
using a synthetic peptide derived from the same region of the
protein as an acceptor. Furthermore, human B-lymphoblas-
toid cells, which secrete IL-12, were found to contain an en-
zyme that carries out the C-mannosylation reaction. This
shows that nonrecombinant IL-12 is potentially C-mannosy-
lated as well. This is only the second report on a C-mannosy-
lated protein. However, the occurrence of the C-mannosyl-
transferase activity in a variety of cells and tissues, and the
presence of the recognition motif in many proteins indicate




Only one C-mannosylated protein, human RNase 2, has been
reported so far (Hofsteenge et al., 1994; de Beer et al., 1995;
Löffler et al., 1996). C-Mannosylation was discovered in
endogenous RNase 2 purified from human urine and human
blood cells (Löffler et al., 1996) and was also found in
recombinant RNase 2 (Krieg et al., 1997). This raises the question
as to how general this type of glycosylation is. Although indirect
evidence strongly suggests that other C-mannosylated proteins
exist (Krieg et al., 1997, 1998), no direct proof is available.
C-Mannosylation of RNase 2 involves the attachment of an
α-mannosyl residue via a C-C link to the indole moiety (Figure
1) of the first tryptophan in the recognition sequence Trp-x-x-Trp
(Krieg et al., 1998). It has been shown that a microsomal
transferase which uses Dol-P-Man as the sugar donor is involved
(Doucey et al., 1998). This C-mannosyltransferase activity is
present in a variety of cultured mammalian cells, but not in cells
from insects, plants or E.coli (Krieg et al., 1997). A search of the
Fig. 1. Structure of C2-α-mannosyltryptophan [(C2-Man-)Trp].
Swiss-Prot and TrEMBL databases yielded 336 secreted mam-
malian proteins containing the motif, including human IL-12
(Krieg et al., 1998).
IL-12 (also called cytotoxic lymphocyte maturation factor) is
a cytokine that is structurally unique among the interleukins in
that it is a heterodimer composed of two disulfide-linked chains.
The α-chain is 253 amino acids long and contains three potential
N-glycosylation sites, whereas the β-chain consists of 328 amino
acids with five potential N-glycosylation sites in addition to a
C-mannosylation site at the C-terminal end (position
319β–322β). IL-12 plays a central role in the immune system by
promoting the development of type 1 T-helper cells and by
regulating cellular functions of T- and natural killer cells
(Trinchieri et al., 1994; Hendrzak et al., 1995). It has great
therapeutic potential because of its potent antitumor activity. This
is presently leading to clinical trials, including gene therapy
(Tahara et al., 1995), for the treatment of human cancer (Zitvogel
et al., 1995). Furthermore, IL-12 has been demonstrated to be
active in several mouse models of infectious diseases caused by
viruses, protozoans, fungi, and mycobacteria (Gately et al.,
1996).
Here we demonstrate by ESIMS analysis and NMR spectro-
scopy that rHuIL-12 from CHO cells is partially C-mannosylated
on Trp-319β. This raises the question as to whether nonrecombin-
ant IL-12 is also modified. Toward this aim, the presence of the
C-mannosyltransferase in human B-lymphoblastoid cells




Fig. 2. Characterization of the modified C-terminal peptide from rHuIL-12. (A) Reduced and carboxamidomethylated rHuIL-12 was digested with trypsin, and
the two C-terminal peptides (a and b) were isolated by LC-ESIMS (upper panel) and characterized by nanospray ESIMSMS. The spectra of peptide a and b are
shown in the lower panels. The numbers indicate the m/z. (B) The ESIMSMS spectrum of the modified peptide (“a) is shown. Ions with m/z 162 amu larger than
in the unmodified peptide have been underlined. The loss of 120 Da from the b12- and the [M+2H]2+ ion has been indicated with “120 an “60, respectively. (C)
Edman degradation of peptide “a of rHuIL-12. The phenylthiohydantoin amino acid observed at cycle 6 (lower trace) coelutes with the (C2-Man-)Trp derivative
obtained from position 7 of RNase 2 (upper trace).
Results
rHuIL-12 from CHO cells is C-mannosylated
To examine whether Trp-319 of the β-chain of rHuIL-12 is
C-mannosylated, tryptic peptides were isolated from the reduced
and carboxamidomethylated protein. The C-terminal tryptic
fragment of the rHuIL-12 β-chain was isolated by reversed phase
HPLC interfaced with LC-ESIMS. Two peptides from this region
of the molecule were isolated, peak “a, eluting at 39.6 min, and
peak “b, eluting at 44.1 min, with a mass of 1957 and 1795 Da,
respectively (Figure 2A). The 162 Da higher mass and shorter
elution time of peptide “a strongly suggested it to be mono-
hexosylated (Hofsteenge et al., 1996). The ion count of the
modified peptide was 20% of that of the unmodified peptide
suggesting that the ratio of the modified to unmodified peptide
was approximately 1:5. Both peptides were purified to homo-
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Fig. 3. Part of the 600 MHz TOCSY spectrum at 300 K of the peptide
comprising residues 316β-322β of rHuIL-12, recorded with a mixing time of
80 ms. The resonance assignment of the modification is indicated in the
1-dimensional spectrum placed on top. Crucial cross peaks are boxed and
annotated. The peptide is identified as S-S-S-(C2-Man-)W-S-E-W.
Non-annotated peaks are α-β connectivities of Ser and Trp.
geneity and analyzed by ESIMSMS. The spectrum of peptide “a
(Figure 2B) showed that the ions b5 and y3 to y7 had the same m/z
values as in the unmodified peptide “b, whereas those of b8 to b12
and y10 to y11 were 162 atomic mass units (amu) higher. This
demonstrated that the modification was located either on
Trp-319β, Ser-320β, or Glu-321β. The ion at 1023.0 amu could
either be the unmodified y9- or the modified b7 ion, which
restricted the localization of the modification to Trp-319β or
Ser-320β. Previously, a characteristic 120 Da loss has been
observed in MSMS experiments of (C2-Man-)Trp-containing
peptides from RNase 2 (Hofsteenge et al., 1996). The same was
observed here (Figure 2B). To determine the position of the
modified amino acid, peptide “a was subjected to Edman
degradation, which yielded the sequence Y-Y-S-S-S-W*-S-E-W-
A-S-V-P-C-S. The PTH-derivative of the residue at position 6 of
the peptide (W*) comigrated exactly with that of (C2-Man-)Trp
in RNase 2 (Figure 2C).
In order to obtain unequivocal proof for the identity of the
hexosyl residue, the chymotryptic peptide comprising residues
316β-322β was analyzed by NMR spectroscopy. Figure 3 shows
the part of the TOCSY spectrum where resonances of the
non-amino-acid substituent are observed. The assignment of its
resonances followed readily from the spectrum. The chemical
shifts (Table I) were virtually identical to those reported earlier for
the α-mannopyranosyl moiety linked to C2 of Trp-7 in human
RNase 2 (Hofsteenge et al., 1994; de Beer et al., 1995). Also the
aromatic resonances of the Trp residue were in good agreement
with the published values. The 1-dimensional spectrum was
well-resolved, and the observed coupling constants were in close
agreement with those found for (C2-Man-)Trp (Table I). It should
be noted that the chemical shifts differed significantly from the
ones published for O-mannosylated Ser, present in a small protein
(Bergwerff et al., 1998). This further confirms that Ser-320 is not
modified.
Table I. Chemical shifts and J-couplings of the C-glycosylated amino acid
residue, obtained at 300 K
Chemical shift (ppm) 3J-Coupling (Hz)
IL-12 residue 319β RNase 2a
residue 7
IL-12 residue 319β RNase 2a
residue 7
H1′ 5.18 5.22 J1′2′ 7.5 7.8
H2′ 4.44 4.42 J2′3′ 3.0 3.2
H3′ 4.07 4.09 J3′4′+ J4′5′ 9.1 9.3
H4′ 3.93 3.96 J5′6′ 8.3 8.3
H5′ 3.83 3.87 J5′6′′ 3.4 3.3





Chemical shifts were referenced against internal acetone (δ = 2.225;
Vliegenthart et al., 1983). The notation for the atoms is as depicted in Figure 1.
aThese values were taken from Hofsteenge et al. (1994).
The C-terminal peptide of IL-12-β is a substrate for the
C-mannosyltransferase
The results described above predict that the C-terminal peptide of
the IL-12-β chain should be an acceptor for the C-mannosyltrans-
ferase. Incubation of the peptide Ac-RYYSSSWSEWAS-NH2
with Dol-P-[2–3H]Man and rat liver microsomes (55 µg of
protein) for 30 min at 37C resulted in the incorporation of 4.2 ×
104 c.p.m., compared to 1.37 × 103 c.p.m. in a control without
peptide. To obtain sufficient product for a detailed structural
characterization, the peptide was incubated for 20 h at 26C, at
which time 83% of the [2–3H]Man had been transfered from
Dol-P-[2–3H]Man to the peptide. The peptide was treated with
trypsin to remove the N-terminal acetylated Arg and purified. The
purification yielded a single radioactive peptide with a molecular
mass of 1514 Da, corresponding to that of a monomannosylated
peptide (Figure 4A).
The purified radiolabeled peptide was subjected to solid-phase
Edman degradation to determine the site of mannosylation. A
burst of radioactivity appeared with the Trp at position 7 (Figure
4B). Due to its C-terminal blocking group, the peptide was
coupled to the solid-phase through the side chain carboxylate of
the Glu preceding the Trp at position 10. As a result, no
information about this Trp residue was obtained. C-mannosyla-
tion of this residue was excluded by MSMS analysis of the
peptide. All ions containing Trp-7 were 162 Da heavier than those
of the unmodified peptide. Furthermore, no ions with a modified
Trp 10 were identified (data not shown). The presence of a C-C
linkage between the tryptophan and the mannosyl residue was
concluded from the typical 120 Da loss from ions containing Trp
7, as was also found in the peptide from rHuIL-12 (Figure 2B).
M.-A.Doucey et al.
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Fig. 4. In vitro C-mannosylation of synthetic IL-12 peptide. (A) The
radiolabeled peptide was digested with trypsin and fractionated by C8
reversed phase HPLC. The elution of the column was monitored at 214 nm
(upper panel). The lower panel shows the radioactivity; the width of the bar
indicates the fraction size. (B) the purified IL-12 radiolabeled peptide was
subjected to solid-phase Edman degradation and the radioactivity of the
anilinothiazolinone amino acid released at each cycle was measured.
IL-12 secreting B-lymphoblastoid cells contain the
C-mannosyltransferase
The question remains whether nonrecombinant IL-12 is also
C-mannosylated. The direct analysis of endogenous IL-12 is not
practical due to its extremely low abundance. Stern et al. (1990)
obtained only 10 µg of purified IL-12 from 60 l of conditioned
medium from EBV-transformed lymphoblastoid cells. This can
be compared with the 9.6 mg used in the complete analysis of the
C-mannosylation of the recombinant protein by MS and NMR.
As an alternative, we examined C-mannosyltransferase activity in
IL-12 secreting NC-37 cells. Incubation of NC-37 cell micro-
somes with Dol-P-[2–3H]Man and the IL-12 derived peptide
(Ac-RYYSSSWSEWAS-NH2), or the general acceptor tetrapep-
tide Ac-WAKW-NH2, resulted in the transfer of radioactivity
from the Dol-P-[2–3H]Man to the peptides (Figure 5A). The
reaction was linear with time (Figure 5B) and its rate increased
with the microsomal protein concentration (Figure 5C). Previous-
ly, rat liver has been shown to contain an enzyme that catalyzes
protein C-mannosylation (Doucey et al., 1998). Heat-treatment
of microsomes from NC-37 cells abolished C-mannosyltransfer-
ase activity (Figure 5A). Furthermore, the reaction displayed a
rectangular hyperbolic dependence on the concentration of the
peptide substrate (Figure 5B, inset). Treatment of the microsomes
with chymotrypsin strongly decreased the rate of the reaction
(data not shown). In RNase 2 the sequence Trp-x-x-Trp is the
recognition signal for C-mannosylation (Krieg et al., 1998).
Therefore, a peptide lacking this motif, Ac-WAKA-NH2, was
examined as a further control. The amount of radioactivity
transferred in this case was the same as the background observed
in the absence of any peptide (Figure 5A). The small amount of
radioactivity found in these controls must be due to incorporation
of mannose into endogenous microsomal acceptors. These results
demonstrate that C-mannosylation is also enzyme-catalyzed in
NC-37 cells.
Discussion
The results presented here show that rHuIL-12 contains
(C2-Man-)Trp at position 319 of the β-chain. Initial evidence was
obtained by ESIMS and Edman degradation of the C-terminal
tryptic peptide. Although these techniques allow the analysis of
picomolar amounts of material, they do not provide unequivocal
identification of the hexosyl moiety. For example, due to the lack
of synthetic standards of the various (C2-hexosyl-)tryptophans, it
cannot be excluded that their PTH-derivatives comigrate on
HPLC following Edman degradation. Unambiguous proof has
been obtained by NMR spectroscopy (Figure 3, Table I). This
showed that the chemical structure of residue 319β is identical to
that of (C2-Man-)Trp present in human RNase 2, which was
previously characterized in detail by the same technique (Hof-
steenge et al., 1994; de Beer et al., 1995). The chemical shifts of
the (C2-Man-)Trp residue in the peptide from IL-12 [S-
S-S-(C2-Man-)W-S-E-W] are remarkably similar to those found
in the peptide from human RNase 2, which has a different primary
structure [F-T-(C2-Man-)W-A-Q-W]. Both peptides are pre-
sumably disordered. The J-couplings of the mannosyl residue in
both peptides differ substantially from those expected for the
regular chair conformation. Previously, it has been concluded that
the sugar moiety, at least in the peptide, does not adopt one, but
several conformations (de Beer et al., 1995). Thus, the present
data also show that the conformational dynamics of the mannosyl
residue is the same in the two peptides.
Protein C-mannosylation
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Fig. 5. C-Mannosyltransferase activity in IL-12 producing cells. (A) The
presence of C-mannosyltransferase activity in microsomes from NC-37 cells
was determined by incubation of acceptor peptide (0.9 mM) with 0.9 µM
Dol-P-[2–3H]Man (5.61 Ci/mmol) and NC-37 cell microsomes (55 µg of
protein) for 30 min at 37C. After extraction with chloroform/methanol (3/2,
v/v), the radioactivity in the aqueous phase was determined. Peptide 1
corresponds to the IL-12 derived dodecapeptide: Ac-RYYSSSWSEWAS-NH2.
Peptide 2 and peptide 3 correspond to the tetrapeptides Ac-WAKW-NH2 and
Ac-WAKA-NH2, respectively. In the experiment indicated with “b microsomes
were heated at 95C for 8 min, before the assay was performed. (B) The time
dependence of the in vitro C-mannosylation reaction was examined using the
peptide Ac-WAKW-NH2. The reaction was stopped by extraction with
chloroform/methanol (3/2, vol/vol) at the indicated time the amount of
radioactivity in the upper phase was determined (solid circles). Control
experiments were performed without acceptor peptide (open circles). The inset
shows the incorporation of radioactivity after 30 min incubation at 37C, as a
function of the concentration of the same acceptor peptide. The values were
corrected for background by subtracting the values obtained in the absence of
peptide. (C) Dependence of the rate of reaction on the amount of added
microsomes was examined using the peptide Ac-WAKW-NH2. All data shown
represent the average of two independent experiments.
RNase 2 and IL-12 are structurally and functionally unrelated,
indicating that C-mannosylation is not restricted to a single family
of proteins. Trp-319β occurs in the sequence Trp-x-x-Trp, which
in RNase 2 has been demonstrated to be the recognition motif for
the C-mannosyltransferase. This suggests that this sequence may
be general and serve the same role in other proteins as well. The
motif has been found in 336 secreted mammalian proteins
currently present in protein databases (Krieg et al., 1998). It is not
to be expected that all of these will be modified, however, since
their availability may depend on the tertiary structure. Krieg et al.
(1998) and Doucey et al. (1998) have demonstrated that the
primary structure as such is recognized by the transferase, and
concluded that C-mannosylation of RNase 2 must occur before
folding is completed.
Lymphoblastoid cells (NC-37) secrete IL-12 and contain a
microsome-associated protein transferase that carries out the
C-mannosylation reaction. This shows that potentially also
nonrecombinant IL-12 is C-mannosylated. The enzyme from
NC-37 cells has the same requirement for a Trp residue at position
+3 as a signal for C-mannosylation as the transferase from rat
liver microsomes (Krieg et al., 1998). Also the amount of activity
in microsomes from the NC-37 cells is of the same order of
magnitude as that in rat liver.
rHuIL-12 from CHO cells was only partially C-mannosylated
on Trp-319β. The degree of mannosylation depends on the cell
line used (Krieg et al., 1997). With RNase 2, CHO cells were
found to be the least active, yielding 49% C-mannosylation,
whereas, e.g., NIH 3T3 gave 81%. No activity at all was found in
insect cells, plant protoplasts, E.coli (Krieg et al., 1997) and
S.cerevisiae (A.-M. Vicentini and M.-A. Doucey, unpublished
observations). rHuIL-12 has been reported to have the same
biological activity in vitro as the endogenous human protein
(Gubler et al., 1991). If, however, C-mannosylation would in
analogy to N-linked glycans affect parameters such as protein
stability, circulatory lifetime, biodistribution, or uptake (Ras-
mussen, 1992), differences may be found in in vivo investiga-
tions. Because the therapeutic potential of IL-12 was demon-
strated in several mouse models, it is important to note that in
contrast to human IL-12, the protein from mouse does not contain
the C-mannosylation motif. Therefore, the investigation of the
therapeutic potential of rHuIL-12 in mouse models might be
inappropriate.
The use of recombinant proteins in the therapy of human
disease is of increasing importance. To minimize the risks of
unwanted side effects substantial efforts are made to copy the
human endogenous protein as faithfully as possible (Hayes et al.,
1997). This aim is hardly reached completely, due to heterogene-
ity of, e.g., N- or O-linked glycans or, as demonstrated here, the
presence of a new or unexpected posttranslational modification.
A major question that remains to be answered concerns the
presently unknown function of C-mannosylation. In view of the
widespread occurrence of the C-mannosyltransferase in mam-
malian tissues (M.-A. Doucey, unpublished observations), and
the unique stability of the C-C link between the carbohydrate and




NC-37 cells (ATCC CCL214) were grown in RPMI 1640 medium
supplemented with 10% fetal calf serum (Life Technologies/Gibco




rHuIL-12 from CHO cells was a gift from Dr. Alvin Stern, Roche
Research Center, Hoffman-La Roche, Inc., Nutley, NJ (Stern et
al., 1990). The protein was reduced and carboxymethylated
according to the method described previously (Hofsteenge et al.,
1991). Digestion with trypsin (Worthington, Freehold, NJ) and
fractionation of the peptides by reversed phase LC-ESIMS were
performed as described previously (Krieg et al., 1997). The
C-terminal β-chain peptide and its modified counterpart were
detected by extraction of the MS data for ions with m/z 898 and
979 (the [M+2H]2+ ions), respectively. Final purification was
achieved by C8 reversed phase HPLC in 10 mM trimethylamine-
acetate, pH 6.0 (Hofsteenge et al., 1991). Nanospray ESIMSMS
(Wilm et al., 1996) and solid-phase Edman degradation (Pisano
et al., 1993) were performed according to published methods.
NMR spectroscopy
The peptide comprising residues 316β-322β was obtained by
cleaving the tryptic peptide from 9 mg rHuIL-12 (see above) with
chymotrypsin (Worthington, Freehold, NJ), followed by purifica-
tion on a C18 HPLC column. The identity and homogeneity of the
peptide (mass: 1029 Da) were confirmed by Edman degradation.
The peptide was dissolved in D2O and transferred into a
susceptibility matched 5 mm NMR tube (Shigemi Co.,
BMS-005V) with a sample volume of 200 µl. The concentration
was ∼35 µM. Clean-TOCSY spectra (Griesinger et al., 1988)
with mixing times of 40 ms and 80 ms were recorded on a Varian
Unityplus 600 MHz spectrometer equipped with a 1H, 13C, 15N
triple resonance probe head with z-gradients. The 2-dimensional
spectra were folded once in t1, and were acquired with 160 scans
and 176 increments using phase sensitive data acquisition in both
dimensions. Data were processed using the VNMR program.
In vitro C-mannosylation and product characterization
Microsomes from rat liver and NC-37 cells were prepared as
described previously (Graham, 1992), except that in the case of
the cells, the 10,000 × g centrifugation was omitted. The
microsomes were washed with 50 mM phosphate, pH 7.4
containing 150 mM NaCl, 1 mM MgCl2, 20% glycerol, 2 µg/ml
benzamidine, 5 µg/ml pepstatin A, 5 µg/ml leupeptin, and 2 mM
EGTA, frozen, and stored at -80C. Before use the microsomes
were washed with 500 mM NaCl in the same buffer to remove
proteases and endogenous acceptor proteins.
The IL-12 peptide (Ac-RYYSSSWSEWAS-NH2) was
C-mannosylated in vitro using rat liver microsomes as a source of
C-mannosyltransferase and Dol-P-[2–3H]Man as the sugar donor
(Doucey et al., 1998). The reaction mixture contained in a final
volume of 24 µl: 0.9 µM Dol-P-[3H]Man (5.61 Ci/mmol),
0.9 mM of peptide, rat liver microsomes (150 µg of protein),
20 mM Hepes-NaOH pH 7.2, 110 mM K-acetate, 2 mM
Mg-acetate, proteases inhibitors (2 µg/ml benzamidine, 5 µg/ml
pepstatin A, 5 µg/ml leupeptin, 2 mM EDTA), 0.2% Triton
X-100. The reaction was performed at 26C for 20 h and stopped
by adding 2 ml of chloroform/methanol 3:2 (v/v) and 0.48 ml of
water. The long incubation period was necessary to obtain
sufficient quantity of modified peptide for detailed structural
analysis. The aqueous phases of 12 experiments were combined
and dried. The peptide was isolated by chromatography using a
C18 Sep-Pak cartridge (Waters, Milford, MA) and purified by
reversed phase HPLC at pH 6.0 (see above). The purified peptide
was digested with trypsin and fractionated by C8 reversed phase
LC-ESIMS (Krieg et al., 1997). Final purification was achieved
by re-chromatography. The purified radioactive peptide was
subjected to nanospray ESIMSMS (Wilm et al., 1996) and to
solid-phase Edman degradation (Pisano et al., 1993).
C-Mannosyltransferase activity in microsomes from NC-37
cells was assayed with the IL-12 derived peptide, as well as the
general acceptor peptide Ac-WAKW-NH2 . In the standard assay
the reaction mixture contained in a final volume of 24 µl: 0.9 mM
of peptide, 0.9 µM Dol-P-[2–3H]Man (5.61 Ci/mmol) and
microsomes from NC-37 cells (55 µg of protein) in the buffer
described above (Doucey et al., 1998). The Triton X-100/protein
ratio was always kept constant at 0.34 (w/w). The reaction was
stopped after 30 min at 37C by adding 2 ml of chloroform/meth-
anol 3:2 (v/v) and 0.48 ml of water. After centrifugation, the
upper, aqueous phase contained the peptide and the lower, organic
phase the Dol-P-[3H]Man. The radioactivity in 0.2 ml of the
upper phase was determined by scintillation counting. As
controls, either the peptide or microsomes were omitted, or the
peptide was substituted with a homolog missing the C-manno-
sylation motif (Ac-WAKA-NH2). Furthermore, microsomes
were heated or treated with chymotrypsin as described previously
(Doucey et al., 1998).
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